Cannabis producer Aurora Cannabis (NYSE: ACB) reiterated its production and revenue guidance for the fourth quarter and fiscal 2019 after evaluation of its business conceded strong delivery. The global cannabis market is a rapidly developing business opportunity and the company intends to dominate the industry in terms of scale and profitability.
The company predicts net revenues in the range of $100 million to $107 million and net cannabis revenue in the range of $90 million to $95 million for the fourth quarter. The growth is anticipated to be across all key business segments including medical, both Canadian and international, and consumer markets.
Production available for sale for the fourth quarter is expected to be at the upper end of the 25,000 to 30,000 kilograms range, ahead of its previous forecast of 25,000 kilograms. For fiscal 2019, Aurora Cannabis anticipates total revenues in the range of $249 million to $256 million.
With the implementation of new regulations permitting the sale of a broader portfolio of derivative products later this year, the company plans to allocate a sizable fraction of this production of the inventory for further processing. This will ensure a broad portfolio of new products in sufficient quantities available for sale is under Aurora’s hood when the higher-margin products will be permissible in Canada.
The evolving market is now estimated to be $3 billion annual medical and $9 billion annual adult-use markets in Canada, according to reports from BMO Capital Markets and Deloitte. Further, the legalization of cannabis products could increase the estimated future global market to over $70 billion annual medical and $115 billion annual adult-use consumption.
In stiff competition with other companies, Aurora Cannabis is expected to invest significantly in research and development, market development, marketing, production expansion, new client identification, distribution channels, and client support. The company believes in its ability to achieve competitive per-unit costs through increased production and to recognize higher margins through the sale of higher-margin products.
Also read: Tilray faces doubts of cannabis risks
For the third quarter, Aurora Cannabis reported a wider loss due to higher costs and expenses despite a 305% jump in revenue. In Q3 2019, Aurora produced 15,590 kilograms of cannabis compared to 7,822 kilograms in the prior quarter and 1,206 kilograms in the prior-year quarter.
Shares of Aurora ended Monday’s regular session down 2.21% at $6.19 on the NYSE. Following the reiteration release, the stock advanced over 6% in the premarket session.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Deere & Company (DE) Q2 2025 earnings fall on lower revenues
The Deere & Company (NYSE: DE), a leading manufacturer of agricultural and construction equipment, on Thursday reported a double-digit fall in revenue and net income for the second quarter of 2025. The company's
Key metrics from Alibaba Group’s (BABA) Q4 2025 earnings results
Alibaba Group Holding Limited (NYSE: BABA) reported its fourth quarter 2025 earnings results today. Revenue was $32.5 billion, up 7% year-over-year. Net income attributable to ordinary shareholders was $1.70 billion.
WMT Earnings: All you need to know about Walmart’s Q1 2026 earnings results
Walmart Inc. (NYSE: WMT) reported its first quarter 2026 earnings results today. Total revenue of $165.6 billion was up 2.5%, or 4% in constant currency, year-over-year. Net sales of $164
Comments
Comments are closed.